All

Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
16 October 2025

Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463

Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has...

Read more
Sunrise Group: $29 Million Raised For Expanding Dreem Health
1 October 2025

Sunrise Group: $29 Million Raised For Expanding Dreem Health

Sunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep...

Read more
With a €860,000 investment, Seventure Partners joins Kapsera’s funding round, raising its Series A to €5 million.
22 September 2025

With a €860,000 investment, Seventure Partners joins Kapsera’s funding round, raising its Series A to €5 million.

Kapsera, a pioneer in sustainable microencapsulation for the agri-food industry, announces the entry of Seventure Partners into its capital as part of its Series A financing...

Read more
First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis
2 September 2025

First Patient Dosed In Citryll’s Phase IIA Trial Evaluating CIT-013 In Rheumatoid Arthritis

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today...

Read more
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
2 June 2025

Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...

Read more
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
30 May 2025

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing...

Read more
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
18 March 2025

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more
SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption
21 February 2025

SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption

SeaWeed Concept, start-up specializing in the use of lacto-fermented seaweed for human consumption, has just raised 2 million euros from the Paris-based Blue Forward Fund. This...

Read more
Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.
6 February 2025

Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.

Anybuddy, France's leading racquet sports booking platform, has announced a €2 million round of financing to support its expansion and enhance its service offering.
By...

Read the press release
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
21 January 2025

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more